03 Sep 2010 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Sep 2010
Therapeutic Registrations by SWOG Institutions Only (Txca=Y)
67% of Calendar Year is Past
Projected 12 Month
2010 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2010 (Decrease) Last (Decrease)
Committee 2009 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 2292 889 39% 1319 <973> 1459 <833>
GI 411 278 68% 412 1 395 <16>
GU 599 316 53% 469 <130> 506 <93>
GYN 0 23 34 34 23 23
LEUK 192 96 50% 142 <50> 141 <51>
LUNG 270 291 108% 432 162 399 129
LYMPH 95 91 96% 135 40 131 36
MELAN 97 34 35% 50 <47> 92 <5>
MMYEL 64 54 84% 80 16 73 9
TM 41 43 105% 64 23 52 11
------------ ---------- --------- ---------- --------- ----------
4061 2115 3138 <923> 3271 <790>
03 Sep 2010 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Sep 2010
Non-Therapeutic Registrations by SWOG Institutions Only
67% of Calendar Year is Past
Projected 12 Month
2010 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2010 (Decrease) Last (Decrease)
Committee 2009 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 10 8 80% 12 2 9 <1>
CC 33 212 642% 315 282 245 212
LEUK 318 68 21% 101 <217> 143 <175>
LUNG 39 17 44% 25 <14> 21 <18>
LYMPH 42 39 93% 58 16 58 16
MMYEL 75 65 87% 96 21 92 17
------------ ---------- --------- ---------- --------- ----------
517 409 607 90 568 51
03 Sep 2010 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Sep 2010
All Initial Registrations by SWOG Institutions
67% of Calendar Year is Past
Projected 12 Month
2010 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2010 (Decrease) Last (Decrease)
Committee 2009 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 2302 897 39% 1331 <971> 1468 <834>
CC 33 212 642% 315 282 245 212
GI 411 278 68% 412 1 395 <16>
GU 599 316 53% 469 <130> 506 <93>
GYN 0 23 34 34 23 23
LEUK 510 164 32% 243 <267> 284 <226>
LUNG 309 308 100% 457 148 420 111
LYMPH 137 130 95% 193 56 189 52
MELAN 97 34 35% 50 <47> 92 <5>
MMYEL 139 119 86% 177 38 165 26
TM 41 43 105% 64 23 52 11
------------ ---------- --------- ---------- --------- ----------
4578 2524 3745 <833> 3839 <739>
03 Sep 2010 Southwest Oncology Group Current and Projected Accrual by Committee
Data as of 03 Sep 2010
Initial Registrations to Cancer Control Studies
67% of Calendar Year is Past
Projected 12 Month
2010 Percentage Projected Increase Accrual Increase
Base Accrual Accrual of Base 2010 (Decrease) Last (Decrease)
Committee 2009 to date Accrual Accrual from Base 12 Months from Base
--------- ------------ ---------- ---------- --------- ---------- --------- ----------
BREAST 188 41 22% 61 <127> 70 <118>
CC 33 212 642% 315 282 245 212
GU 496 160 32% 237 <259> 310 <186>
LUNG 81 24 30% 36 <45> 42 <39>
LYMPH 4 6 150% 9 5 9 5
------------ ---------- --------- ---------- --------- ----------
802 443 657 <145> 676 <126>
03 SEP 2010 Southwest Oncology Group Open and Temporarily Closed Studies
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.
Monthly Date of
Stat Open Months Total Accrual Accrual Expected Closure or
Comm. Phase Study Center Date Open Regs Goal Rate Temporary Closure
------ ------ -------------------------------------- -------- ---------- ------ ------ ------- ------- --------------------
BREAST II S0622 Breast, Adv, 2 sched Dasatinib SWOG 15-MAR-07 41 76 80 1.8 Nov-2010
Z1071 Node+, chemo + LN dissect ACOSOG 22-JUL-09 15 2.2
S0800 Brst,Neoadj nabPAC+/-Bev->AC+G SWOG 01-APR-10 5 12 200 2.4 Apr-2017
C40603 Carb/Bev+Neoadj Pac, then AC/EC CALGB 21-MAY-10 0 .0
III C40101 Breast, Adj, Node neg, AC vs T CALGB 15-MAY-02 733 1.5
JMA20 Breast, Early, Regional RT NCIC 03-OCT-02 8 .0
IBC24-02 Ovar Ftn suppress/premeno IBCSG 04-AUG-03 187 .3
S0230 Breast,Adj,Chemo +/- Goserelin SWOG 01-OCT-03 83 231 458 3.0 Dec-2016
S0221 Breast,Adj,N+,ACvAC+G/Pac q1v2 SWOG 01-NOV-03 82 2681 3250 19.8 Jan-2013
B39 Stg 0-2, whole vs partial RT NSABP 22-MAR-05 14 .0
C70301 QOLEmployInformCareCost Analysi CALGB 24-OCT-05 35 .0
s
N0434 JMA27 Companion Study NCCTG 08-DEC-05 100 .0
JMA27B 5yr Adj Anast vs Exemestrane NCIC 24-APR-06 94 .0
PACCT-1 Assess of Ca Clinical Tests ECOG 24-APR-06 1700 36.5
C40302 Endocrine +/1 Inhibition CALGB 22-SEP-06 28 1.0
S0500 Brst,Adv,CTC,mntain v chnge tx SWOG 01-OCT-06 47 437 500 14.7 Jan-2011
E1105 Adv, Trastuzumab +/- Bev ECOG 21-NOV-07 15 .0
N063D ALTTO NCCTG 15-FEB-08 80 5.7
C40503 EndocrineTxCombo w/AntiVEGF Tx CALGB 22-MAY-08 7 1.2
N0733 Her2+, Cap + Lap +/- IMC-A12 NCCTG 30-JUL-08 2 .3
C40601 NeoAdj, Her-2+, Pac+Trast or La CALGB 08-DEC-08 5 .8
p
MA.32 Metformn vs Placebo NCIC 08-JUL-10 0
CC III S0715 ALC Taxane-induced neuropathy SWOG 15-SEP-09 11 245 380 29.5 Jan-2011
GI II S0809 EHCC,Adj,Cape+Gem==>Cape+RT SWOG 01-DEC-08 21 32 88 3.7 Dec-2011
S0713 Rect,Stg2-3,Ox/Cape/Cet+RT->SRG SWOG 01-FEB-09 19 13 88 1.3 May-2015
S0941 GallChol,Adv,Sorafenib/Erlotinib SWOG 15-APR-10 4 3 55 .6 May-2017
III R04 Rectum, Capecitabine vs 5FU NSABP 09-AUG-04 49 .7
E5202 Colon,Stg2,5FU/Leuc/Oxal +/- Bev ECOG 08-AUG-05 356 6.7
C80405 GI,Met,FOLFOX/FIRI,Bev,Cetux CALGB 26-SEP-05 527 2289 5.7
S0600 COLREC,MET,CHEMO+CETUX OR BEV SWOG 15-JUN-07 38 69 671 2.0 > 15 Yrs
S0518 Carcinoid,Adv,Octreo/Alpha/Bev SWOG 01-DEC-07 33 247 283 7.5 Jan-2011
E1208 Chemo Soraf. in Unresect HCC ECOG 09-NOV-09 0 .0
R0848 Panc, Adj, Erlotinib v ChemoRT RTOG 08-DEC-09 0 .0
C80702 Adj FOLFOX+Celecoxib or Placebo CALGB 22-JUN-10 0
GU III MDA3410 Consolidation chemo MDACC 08-MAY-02 21 .2
C90202 Pros,Bone mets,Zoledronic acid CALGB 15-JAN-04 59 1.3
R0521 AS+RT vs AS+RT+Chemo RTOG 22-DEC-05 18 .0
R0415 Hypofrac v Conv 3D-CRG/IMRT RTOG 24-APR-06 1 .0
E2805 Renal, Adj Sunitib v Sorafinib ECOG 08-MAY-06 583 12.0
E3805 CHAARTED ECOG 08-AUG-06 62 2.7
R0524 Pac + Trastuzumab vs Pac alone RTOG 08-DEC-06 5 .0
C90203 Pros, Surgery +/- Neoadj Chemo CALGB 22-DEC-06 58 2.3
S0337 Blad, Instill Gem vs Saline SWOG 15-JUL-07 37 138 340 8.0 Oct-2012
PR11 Pros, Local, Watch vs Active Tx NCIC 15-JUL-07 6 .0
E2804 BeST Trial ECOG 21-MAR-08 38 1.0
C90601 Trans cell, blind bev vs placeb CALGB 07-AUG-09 14 2.2
o
GYN II S0904 GYN,OVAR,Doc +/- Vandetanib,II SWOG 15-MAR-10 5 23 132 4.1 Nov-2012
LEUK BIOL S9007 Cytogen. Studies in Leuk. Pts. SWOG 15-JUL-91 229 3314 2.8
S9910 Leuk Central Lab/Tissue Repos SWOG 15-APR-99 136 1265 2.7
II E1905 MDS/CMMoL/AML-TLD,Aza+/-MS-275 ECOG 01-OCT-06 47 22 123 .2
S0535 APL,High Risk, ATRA/arsenic/GO SWOG 15-NOV-07 34 77 Jun-2010 Temp Close
C10403 ALL <30 yrs-Ped,Chemo. Regimen CALGB 15-JAN-08 31 27 300 2.0
S0703 AML, age 60+, Azacitidine G.O. SWOG 01-DEC-08 90 153 Jun-2010 Temp Close
C10404 CLL, Flu/Rituxan combinations CALGB 15-MAR-09 17 6 300 .3
S0919 Rel AML: Pravastatin+Ida+Ara-C SWOG 15-AUG-09 12 7 55 .8 Jun-2015
S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT SWOG 01-SEP-09 12 1 94 .2 > 15 Yrs
S0910 Rel ph-,B-ALL,Epratuzumab+Cy+Clo SWOG 15-AUG-10 0 0 35
III C10603 PKC 412, blinded, FLT3 AML CALGB 22-APR-08 13 1.3
E2905 MDS, Len vs Len + Epo ECOG 09-FEB-09 12 .7
LUNG I-II S0905 Mesothem,cediranib+chemo,PhI/II SWOG 15-MAR-10 5 5 128 .9 Mar-2022
II S0635 Bac, Stg IIIB/IV Bev + OSI-774 SWOG 15-JUL-07 37 68 88 1.8 Jul-2011
S0720 NSCLC,Stg I,ERCC1/RRM1 to Adj Tx SWOG 15-NOV-08 21 39 60 3.3 Mar-2011
S0722 Mesothelioma, RAD001 SWOG 01-DEC-08 21 29 60 1.5 May-2012
S0709 NSCLC, Adv, PRO+, OSI-774+-Chemo SWOG 01-DEC-08 21 8 110 .3 > 15 Yrs
S0802 ESCLC,Topotecan+/-AVE0005,PhII SWOG 15-MAY-09 15 78 190 7.8 Nov-2011
III E1505 Stg IB-IIIA chemo +/- Bev ECOG 22-JUN-07 140 5.0
C140503 NSCL, Lobect v Sublobar resect CALGB 09-JUL-07 9 .5
C30610 SCLC, Thoracic RT CALGB 21-MAR-08 19 .7
S0819 NSCLC, Adv, Chemo/Bev +/-Cet SWOG 15-JUL-09 13 200 1700 19.5 Jan-2017
OTHER S0424 Molecular Epidemiology NSCLC SWOG 01-OCT-05 59 946 980 3.3 Jul-2011
LYMPH BIOL S8819 Lymphoma Immunophenotyping SWOG 15-FEB-89 258 456 .7
S8947 Lymphoma Serum Repository SWOG 15-APR-90 244 922 3.8
S9245 Relapsed Lymph Tissue Submis SWOG 15-MAR-93 209 32 .0
II S0350 NHL, PEGS, Phase II SWOG 15-SEP-05 59 33 30 1.2 Jul-2010
S0801 NHL, Adv, CHOP-R + I-131 + RM SWOG 01-APR-09 17 71 80 6.0 Oct-2010
S0816 HD, Adv, PET-Adapted Therapy SWOG 01-JUL-09 14 62 200 6.7 May-2012
C50604 Resp-Adapt Chemo Pos Emiss Tomo CALGB 22-JUL-10 0
III C50303 R-CHOP v EPOCH-R CALGB 15-SEP-06 26 1.0
CTN0701 Relapsed follic, allo transpla BMT-CTN 23-FEB-09 0 .0
nt
MELAN II S0826 Melan, Adv, SCH 727965, Ph II SWOG 01-JUL-09 14 55 66 1.2 Jun-2011
III E1697 Melan, HDIFN vs Observation ECOG 15-OCT-02 140 1406 2.5
MMYEL BIOL S0120 Asympt Monoclonal Gammopathies SWOG 01-JUN-02 99 330 385 7.8 Apr-2011
S0309 MMYEL Specimen Repository SWOG 15-NOV-03 81 189 .5
II S0115 Mel+PBSCT for High Risk MM+ALA SWOG 01-JAN-04 80 103 110 .3 May-2012
III S0777 MM, Len Dex +/- Bortezomib SWOG 01-APR-08 29 218 484 11.5 Aug-2012
CTN0702 Single v Tandem Autol transpla BMT-CTN 09-JUN-10 0
nt
TM I S0711 Liver dysfunction PK,Dasatinib SWOG 15-OCT-08 22 42 48 3.5 Oct-2010
SWOG StatCtr Home Page